NovaBone Products
NovaBone Products is a Florida-based biomaterials manufacturer and Halma PLC subsidiary that develops FDA-cleared synthetic bone graft substitutes and wound care devices built on its proprietary 45S5 Bioglass platform, serving dental and orthopedic surgeons across 40+ countries through distributors and private label partnerships.
- Company typePrivate
- Founded2002
- HeadquartersJacksonville, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What NovaBone Products does
NovaBone Products, LLC is a privately held U.S. biomaterials company founded in 2002 and headquartered in Alachua, Florida, operating as a wholly-owned subsidiary of Halma PLC (FTSE 100) since 2020. The company develops, manufactures, and distributes synthetic bone graft substitutes and regenerative devices for dental and orthopedic surgeons across more than 40 countries, with product registrations in 46 jurisdictions. Its portfolio serves two primary verticals — orthopedic surgery (spine, foot and ankle, trauma) and dental surgery (periodontal, implant, sinus lift, ridge augmentation) — through brands including NovaBone Putty, NovaBone IRM, NovaBone Dental Putty, Porous Granules, MIS Delivery System, and the newer NovaForm Wound Matrix for advanced wound care.
The company's core technology is the proprietary 45S5 Bioglass (Calcium Sodium Phosphosilicate) platform, originating from Dr. Larry Hench's research at the University of Florida. Unlike purely osteoconductive graft materials, NovaBone's formulations claim the first FDA-cleared osteostimulative mechanism (2005) — activating genetic pathways that drive osteoblast proliferation and differentiation. The portfolio is supported by 31 FDA 510(k) clearances, 9 utility patents, ISO 13485 and MDSAP certifications, and 2+ million cumulative clinical applications with documented fusion rates above 90% in retrospective studies.
NovaBone generates revenue primarily through one-time hardware sales of its medical devices via a global exclusive distributor network (including BEGO in Europe and Summit Products Group for U.S. wound care), supplemented by private label/OEM manufacturing contracts with tier-one dental brands. The company operates a 30,000 sq ft manufacturing facility with 8,000 sq ft of ISO Class 7 clean rooms in Alachua, FL, employs 51-100 people, and maintains offices in Jacksonville, FL and a regional presence in Shenzhen, China. Recent strategic activity (2023-2025) indicates active expansion into the wound care vertical, the spine interbody fusion segment, and European dental channels through new distribution partnerships.
NovaBone Products firmographics
Firmographics- Name
- NovaBone Products
- Legal name
- NovaBone Products, LLC
- Website
- https://novabone.com
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- NovaBone Products is a Florida-based biomaterials manufacturer and Halma PLC subsidiary that develops FDA-cleared synthetic bone graft substitutes and wound care devices built on its proprietary 45S5 Bioglass platform, serving dental and orthopedic surgeons across 40+ countries through distributors and private label partnerships.
- Ownership category
- akta.pro rank
NovaBone Products industry classification
Industry- Product category
- Orthopedic & Dental Biomaterials
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Dental Equipment and Supplies Manufacturing (339114), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841), Dental Equipment & Supplies (3843)
- akta.pro primary industry
- Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)
- akta.pro secondary industries
- Dental Implants & Prosthodontic Components (Implants/Abutments/Prosthetics) (HLAHAEAE), Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), Periodontal Regeneration (GTR/EMD/Biologics) (HLABACAI)
Keywords
Where NovaBone Products is headquartered
LocationHeadquarters
- HQ city
- Jacksonville
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
NovaBone Products business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales
Revenue model
- Synthetic Bone Graft Products: NovaBone generates revenue through the sale of its proprietary bioactive synthetic bone graft devices (NovaBone Putty, NovaBone IRM, Porous Granules) in multiple delivery formats (syringes, clamshells, cartridges). Products are sold to hospitals, surgical centers, and directly to dental and orthopedic surgeons through a global distributor network. Revenue is primarily one-time device purchase driven by surgical procedure volume.
- Advanced Wound Care Products: Revenue from the NovaForm Wound Matrix, a collagen-based wound dressing cleared by FDA in 2023 for advanced wound care applications. Distributed through Summit Products Group in the U.S. market. Represents NovaBone's expansion into the advanced wound care market.
- Private Label Manufacturing: NovaBone manufactures private-label wound dressings for various tier-one dental brands and other medical device companies. This OEM/OEM model provides recurring revenue from established brands seeking to leverage NovaBone's manufacturing capabilities (ISO 13485, MDSAP certified, 30,000 sq ft of manufacturing space with ISO Class 7 clean rooms).
- International Distribution: Revenue from international markets through a network of country-specific distributors. NovaBone products are registered in 46 countries. Key markets include Europe (via BEGO partnership), Asia Pacific (China, India, Australia), Latin America, Middle East, and Africa. Each market has local distributor arrangements with product codes.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Medical device pricing through distributor network |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
NovaBone Products product offering
Product offeringCore offering
NovaBone Products manufactures and sells proprietary synthetic bone graft substitutes and advanced wound care devices based on its 45S5 Bioglass (Calcium Sodium Phosphosilicate) technology platform. The company offers osteostimulative putties, irrigation-resistant matrices, porous granules, and collagen-based wound matrices for dental surgeons and orthopedic surgeons. NovaBone also provides OEM/private label manufacturing of wound dressings for tier-one dental brands, distributing through a global network of exclusive distributors in more than 40 countries.
Product overview
NovaBone Products is a medical device company specializing in bioactive synthetic bone graft solutions for dental and orthopedic applications. The product portfolio centers on 45S5 Bioglass-based biomaterials that harness osteostimulation properties to promote natural bone regeneration. The core offerings include NovaBone IRM (irrigation-resistant matrix) and NovaBone Putty for orthopedic applications, NovaBone Dental Putty and Porous Granules for dental procedures, and NovaForm Wound Matrix for advanced wound care. NovaBone pioneered the first FDA osteostimulative claim and offers the broadest portfolio of regenerative grafting devices with multiple delivery systems including syringes, cartridges, and clamshell formats. The company operates manufacturing facilities in Alachua, Florida with 30,000 sq ft of space including 8,000 sq ft of ISO Class 7 clean rooms, and holds 31 FDA 510(k) clearances with distribution across over 40 countries.
Differentiator
Problem solved
Functional benefit
Brands
- NovaBone IRM: Irrigation Resistance Matrix series of NovaBone grafting material designed to optimize osteogenesis with exceptional handling properties including irrigation resistance.
- NovaBone Putty
- NovaBone Dental Putty
- NovaBone Porous Granules
- NovaForm Wound Matrix
Products and services
- NovaBone Putty Synthetic bone graft substitute (putty) for orthopedic applications, ready to use out of the package, demonstrating clinical equivalence to autograft with significantly less blood loss and >90% fusion rates. Now cleared for intervertebral disc space applications alongside interbody fusion devices.
- NovaBone IRM (Irrigation Resistance Matrix) Irrigation-resistant bone grafting material for orthopedic use with exceptional handling properties, equivalence to autograft with osteogenic stimulation and angiogenic potential. Available in 2.5cc, 5cc, and 10cc volumes.
- MIS Cartridge Delivery System with Tip Minimally invasive surgery delivery system with conical tip accessory for superior precision, designed to backfill spaces as small as 3.5mm in diameter with consistent smooth putty flow. Available in 10cc and 15cc configurations.
- NovaBone Dental Putty Next-generation Calcium-Phosphosilicate bone substitute engineered for dental applications, ready to use, pre-mixed, cohesive, and moldable. Available in cartridges, syringes, and clamshell formats for periodontal/infrabony defects, ridge augmentation, extraction sites, sinus lifts, and cranio-facial augmentation.
- NovaBone Porous Granules (Dental Morsels) Next-generation synthetic bone graft with interconnected porosity (65% porosity, pore sizes up to 200 microns) for quicker bone integration and remodeling. Indicated for guided bone regeneration, ridge augmentations, and sinus elevations; resorbs over 12-18 months.
- Foot and Ankle Bioglass Syringe Delivery System NovaBone's first foot and ankle-specific 45S5 bioactive glass putty delivery system, commercially available in 2.5cc and 5cc formulations for targeted delivery in small osseous defects in foot and ankle procedures.
- NovaForm Wound Matrix FDA-cleared collagen + 45S5 bioactive glass wound care device for management of partial and full-thickness wounds including pressure ulcers, venous ulcers, diabetic ulcers, and surgical wounds. Fully resorbable, sterile, single-use, distributed in the U.S. through Summit Products Group.
Quantifiable outcome
- >90% fusion rates demonstrated in retrospective clinical studies at Sewickley Hospital (Pittsburgh, PA) and Texas Spine Care Center (San Antonio, TX)
- +3 more outcomes
Companies that use NovaBone Products
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles2 records
NovaBone Products technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
NovaBone Products partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Summit Products GroupcoreNovaBone entered a long-term strategic partnership with Summit Products Group to distribute NovaForm Wound Matrix across the United States. Summit Products Group serves as a key distributor leveraging its deep distribution network and strong presence in post-acute and outpatient care settings. This partnership marks NovaBone's significant expansion into the advanced wound care market.
- BEGOcoreNovaBone entered a strategic distribution partnership with BEGO to bring NovaBone Dental Putty with Cartridge Dispenser to the European market. BEGO launched the product at IDS 2025 in Cologne, Germany. The partnership leverages BEGO's extensive distribution network and market leadership in European implantology to broaden NovaBone's presence in the European dental market.
- Private Label Dental PartnersminorSince 2015, NovaBone has been manufacturing private-label wound dressings (plugs and tapes) for various tier-one dental brands. These private label partnerships leverage NovaBone's ISO 13485 certified manufacturing capabilities and regulatory expertise to provide established brands with differentiated collagen + bioactive glass wound care products.
Scale indicators10 records
Recent moves7 records
Expansion highlights6 records
NovaBone Products competitors and assessment
Company assessmentDirect peers
- botiss biomaterials: botiss biomaterials is a direct competitor in dental bone regeneration and soft tissue management, offering a portfolio of bone graft substitutes, barrier membranes, and soft tissue grafts used in implantology and periodontology. botiss competes directly with NovaBone's dental putty, granules, and collagen products in European and international markets.
- Geistlich Pharma: Geistlich Pharma is the market leader in dental bone regeneration with its Bio-Oss and Bio-Gide products. Geistlich competes directly with NovaBone's dental putty and porous granules in periodontal regeneration, sinus lifts, and implant procedures, making it the most comparable dental-focused peer.
Emerging players
- Cerapedics: Cerapedics is an emerging player in orthobiologics with its i-FACTOR peptide-enhanced bone graft used in cervical spine procedures. Cerapedics represents next-generation bone graft technology (synthetic peptide) that could compete with NovaBone's bioglass-based osteostimulation in spinal fusion indications.
- Xtant Medical: Xtant Medical is an emerging orthobiologics company offering a portfolio of bone grafts including synthetic, allograft, and demineralized bone matrix products. Xtant competes with NovaBone in spinal fusion and orthopedic bone void filling applications, particularly among cost-conscious ambulatory surgery centers.
Broad incumbents
- Medtronic: Medtronic is a broad incumbent in orthobiologics with its INFUSE Bone Graft (recombinant BMP-2) and MASTERGRAFT products used in spinal fusion and orthopedic procedures. While NovaBone competes in adjacent indications, Medtronic's bundled offerings with spinal hardware create significant indirect competitive pressure across orthopedic accounts.
- Zimmer Biomet: Zimmer Biomet is a broad orthopedic incumbent with bone graft substitute offerings used in joint reconstruction, spine, and trauma procedures. Zimmer Biomet's extensive direct sales force and hospital contracts create indirect competitive pressure on NovaBone's orthopedic product line.
- Smith & Nephew: Smith & Nephew is a broad incumbent in both advanced wound care (collagen-based skin substitutes, ALLEVYN, PICO) and orthopedics. Smith & Nephew's wound care portfolio competes with NovaBone's NovaForm Wound Matrix, while its orthopedic segment creates indirect competitive pressure in bone grafting applications.
- Baxter International: Baxter offers the Actifuse line of synthetic bone graft substitutes (silicate-substituted calcium phosphate) that compete directly with NovaBone's bioactive glass products. Baxter is a broad medtech incumbent with established orthopedic distribution channels and comparable bioactive bone graft technology.
- Integra LifeSciences: Integra LifeSciences operates in both wound care (Integra Dermal Regeneration Template) and orthopedics, making it a broad incumbent comparable to NovaBone's combined bone graft and wound matrix portfolio. Integra's regenerative tissue technologies compete in similar surgical specialties and hospital channels.
- Stryker: Stryker is a broad orthopedic incumbent offering bone graft substitutes including products inherited from the Wright Medical acquisition. Stryker competes with NovaBone in foot and ankle, trauma, and sports medicine bone grafting applications through its extensive orthopedic sales channels.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
NovaBone Products social profiles
Digital presenceNovaBone Products compliance and trust
Trust signalCompliance5 records
NovaBone Products financial estimates
Financial estimateRevenue estimate
Valuation estimate
NovaBone Products leadership team
Management profileNumber of profiles
Profiles8 records
NovaBone Products funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NovaBone Products M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NovaBone Products
What does NovaBone Products do?
NovaBone Products manufactures and sells proprietary synthetic bone graft substitutes and advanced wound care devices based on its 45S5 Bioglass (Calcium Sodium Phosphosilicate) technology platform. The company offers osteostimulative putties, irrigation-resistant matrices, porous granules, and collagen-based wound matrices for dental surgeons and orthopedic surgeons. NovaBone also provides OEM/private label manufacturing of wound dressings for tier-one dental brands, distributing through a global network of exclusive distributors in more than 40 countries.
Is NovaBone Products a public or private company?
NovaBone Products is a private company. It is classified as corporate owned and is currently operating.
When was NovaBone Products founded?
NovaBone Products was founded in 2002. It employs 51 to 100 people.
Where is NovaBone Products based?
NovaBone Products is headquartered in Jacksonville, United States, in the North America region.
How does NovaBone Products make money?
Four revenue lines are on record. Synthetic Bone Graft Products are the primary driver. The others are advanced Wound Care Products, private Label Manufacturing and international Distribution.
Who are NovaBone Products's main competitors?
Direct peers on record are botiss biomaterials and Geistlich Pharma. Emerging players are Cerapedics and Xtant Medical. Broad incumbents are Medtronic, Zimmer Biomet, Smith & Nephew, Baxter International, Integra LifeSciences and Stryker.
Does NovaBone Products have an API?
No public API is recorded for NovaBone Products.
What industry is NovaBone Products in?
NovaBone Products's product category is Orthopedic & Dental Biomaterials. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLAHAEAE, Dental Implants & Prosthodontic Components (Implants/Abutments/Prosthetics). Its NAICS code is 339113 and its SIC code is 3842.